Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Clinical Investigation|June 1, 1994
Plasma lipids in HIV-infected patients: a prospective study in 95 patientsJ Constans, J L Pellegrin, E Peuchant, et al.
Therapeutic Drug Monitoring|July 31, 2001
Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimensI Pellegrin, D Breilh, V Birac, et al.
La Revue De Medecine Interne|January 1, 1993
[Membrane fatty acids and blood antioxidants in 77 patients with HIV infection]J Constans, J L Pellegrin, E Peuchant, et al.
The Journal of Infectious Diseases|July 7, 2000
New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipientsI Pellegrin, I Garrigue, D Ekouevi, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 21, 1998
Foscarnet decreases HIV-1 plasma loadI Devianne-Garrigue, I Pellegrin, R Denisi, et al.
AIDS (London, England)|May 16, 2018
Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adultsPierre Duffau, Alexandra Ozanne, Fabrice Bonnet, et al.
The Journal of Infectious Diseases|July 9, 1999
The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virusJ M Molina, G Chêne, F Ferchal, et al.
Antiviral Therapy|July 19, 2005
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patientsJ M Molina, G Chêuc, F Ferchal, et al.
AIDS (London, England)|May 24, 2001
Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapyN Ngo-Giang-Huong, C Deveau, I Da Silva, et al.
ESMO Open|June 27, 2022
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapyC Blaye, É Darbo, M Debled, et al.
Pageof 4